DRI Healthcare Trust is assessing its rights under the Ekterly royalty agreement as KalVista Therapeutics considers a sale to Chiesi Group, disclosed earlier on Wednesday.
The review includes potential activation of put option and buyback provisions if the Chiesi deal closes, but DRI Healthcare has not yet decided on any actions.
The outcome could affect DRI Healthcare’s entitlement to worldwide net sales of Ekterly, with implications for all parties involved in the proposed acquisition.
Is DRI Healthcare leveraging its contract to demand a bigger payout from the Chiesi deal?
What are the undisclosed royalty costs that Chiesi must now face after the acquisition?
How could a hidden clause threaten a $1.9 billion biotech acquisition?
With insurers restricting access, will this buyout make a breakthrough drug harder to get?
Will a one-time gene therapy make this new HAE drug obsolete?